Paolo A. Ascierto

5 ta ish

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

   James Larkin, Vanna Chiarion‐Sileni, René González +28

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170114

2. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822

3. Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

   Caroline Robert, Georgina V. Long, Benjamin Brady +25

   MaqolaOAOchiq kirish20142 iqtibos

   ABIABI:AkademIndex/2026.other.241891

4. MicroRNAs in melanoma development and resistance to target therapy

   Luigi Fattore, Susan Costantini, Debora Malpicci +5

   Sharh maqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.247313

5. Cancer classification using the Immunoscore: a worldwide task force

   Jérôme Galon, Franck Pagès, Francesco M. Marincola +61

   Sharh maqola20122 iqtibos

   ABIABI:AkademIndex/2026.other.620112